Latest Insider Transactions at Cor Medix Inc. (CRMD)
This section provides a real-time view of insider transactions for Cor Medix Inc. (CRMD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CorMedix Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CorMedix Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 10
2024
|
Joseph Todisco Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,982
-7.65%
|
$134,910
$5.17 P/Share
|
|
Mar 13
2024
|
Joseph Todisco Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
13,561
+3.7%
|
$40,683
$3.74 P/Share
|
|
Jan 12
2024
|
Erin Mistry Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,389
-7.99%
|
$13,167
$3.47 P/Share
|
|
Jan 12
2024
|
Erin Mistry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+47.66%
|
-
|
|
Jan 12
2024
|
Matthew T David Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,216
-9.81%
|
$15,648
$3.47 P/Share
|
|
Jan 12
2024
|
Matthew T David Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+48.47%
|
-
|
|
Jan 12
2024
|
Elizabeth Masson Hurlburt EVP, Head of Clinical Ops. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,603
-7.94%
|
$13,809
$3.47 P/Share
|
|
Jan 12
2024
|
Elizabeth Masson Hurlburt EVP, Head of Clinical Ops. |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+46.3%
|
-
|
|
Jan 12
2024
|
Joseph Todisco Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,781
-3.9%
|
$41,343
$3.47 P/Share
|
|
Jan 12
2024
|
Joseph Todisco Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
133,333
+27.41%
|
-
|
|
Dec 15
2023
|
Alan W Dunton |
BUY
Open market or private purchase
|
Direct |
3,000
+16.44%
|
$9,000
$3.3 P/Share
|
|
Dec 14
2023
|
Alan W Dunton |
BUY
Open market or private purchase
|
Direct |
3,000
+19.67%
|
$9,000
$3.45 P/Share
|
|
Dec 12
2023
|
Kaufman Beth Zelnick Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Nov 17
2023
|
Erin Mistry Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+16.95%
|
$4,000
$4.0 P/Share
|
|
Nov 16
2023
|
Steven W Lefkowitz |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+16.58%
|
$30,000
$2.25 P/Share
|
|
Sep 08
2023
|
Joseph Todisco Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+4.35%
|
$30,000
$3.71 P/Share
|
|
May 18
2023
|
Myron Kaplan |
BUY
Open market or private purchase
|
Direct |
6,000
+3.49%
|
$24,000
$4.54 P/Share
|
|
May 17
2023
|
Paulo F Costa |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
$40,000
$4.65 P/Share
|
|
May 17
2023
|
Alan W Dunton |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+24.49%
|
$12,000
$4.33 P/Share
|
|
May 17
2023
|
Joseph Todisco Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+2.33%
|
$20,000
$4.58 P/Share
|
|
May 17
2023
|
Robert A Stewart |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+47.62%
|
$40,000
$4.37 P/Share
|
|
May 10
2023
|
Joseph Todisco Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,443
-15.46%
|
$187,215
$5.3 P/Share
|
|
Nov 15
2022
|
Joseph Todisco Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+7.63%
|
$60,000
$3.82 P/Share
|
|
Aug 24
2022
|
Joseph Todisco Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,700
+2.07%
|
$14,100
$3.92 P/Share
|
|
May 17
2022
|
Myron Kaplan |
BUY
Open market or private purchase
|
Direct |
5,000
+3.03%
|
$15,000
$3.78 P/Share
|
|
May 16
2022
|
Joseph Todisco Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+4.4%
|
$30,000
$3.38 P/Share
|
|
May 10
2022
|
Joseph Todisco Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
207,469
+50.0%
|
-
|
|
Dec 27
2021
|
Myron Kaplan |
SELL
Bona fide gift
|
Direct |
35,000
-5.36%
|
-
|
|
Dec 06
2021
|
Matthew T David Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+24.1%
|
$8,000
$4.5 P/Share
|
|
Nov 17
2021
|
Matthew T David Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+31.75%
|
$5,000
$5.07 P/Share
|
|
Nov 16
2021
|
Myron Kaplan |
BUY
Open market or private purchase
|
Direct |
10,000
+5.4%
|
$50,000
$5.14 P/Share
|
|
May 21
2021
|
Elizabeth Masson Hurlburt EVP, Head of Clinical Ops. |
SELL
Open market or private sale
|
Direct |
8,000
-100.0%
|
$48,000
$6.92 P/Share
|
|
May 17
2021
|
Myron Kaplan |
BUY
Open market or private purchase
|
Direct |
15,000
+8.33%
|
$90,000
$6.03 P/Share
|